Skip to main content
  • Clinical
      |Clinical
    • Acute Coronary Syndromes
    • Cardiac Surgery
    • Covid-19
    • Heart Failure
    • Heart Health
    • Heart Rhythm
    • Hypertension
    • Interventional Cardiology
    • Mitral Valve
    • Pharmaceutics
    • Structural Heart Disease
    • TAVR
    • Tricuspid Valve
    • Vascular & Endovascular
  • Management
      |Management
    • Chest Pain Guidelines
    • Compensation
    • Economics
    • Education & Training
    • Legal News
    • Patient Care
    • Policy & Regulations
    • Professional Associations
    • Quality
    • Revenue
    • Staffing
  • Technology
      |Technology
    • AI
    • Cardiac Imaging
    • Cath Lab
    • CT
    • CVIS
    • ECG
    • Echo
    • EP Lab
    • Informatics
    • MRI
    • Nuclear Cardiology
    • Remote Monitoring
  • Videos
  • Conferences
      |Conferences
    • ACC
    • AHA
    • ASE
    • ASNC
    • ESC
    • EuroPCR
    • HFSA
    • HRS
    • SCAI
    • SCCT
    • SIIM
    • SNMMI
    • STS
    • TCT
    • VIVA
  • Custom Content
      |Custom Content
    • Experience Stories
    • Webinars & Videos
  • Subscribe
  • Forty Under 40 Award
      |Forty Under 40 Award
    • Class of 2026
    • Class of 2025

Search form

Home

Heart Failure: COVID-19 & myocarditis | Empagliflozin & HFrEF | Can the keto diet prevent HF?

News You Need to Know Today
Heart Failure: COVID-19 & myocarditis | Empagliflozin & HFrEF | Can the keto diet prevent HF?
Tuesday, November 24, 2020
Link to Twitter Link to Facebook Link to Linkedin Link to Vimeo

Editor's Choice: Heart Failure

Top Stories

Myocarditis may be less common among COVID-19 patients than previously believed

Researchers reviewed autopsy data from 22 different studies, sharing their findings in Cardiovascular Pathology.

READ MORE >
covid-19 coronavirus
Share on Twitter Share on Facebook Share on Linkedin

Myocarditis may be less common among COVID-19 patients than previously believed

Share on Twitter Share on Facebook Share on Linkedin
covid-19 coronavirus
Researchers reviewed autopsy data from 22 different studies, sharing their findings in Cardiovascular Pathology.
READ MORE >

Risk of death nearly doubles when hospitalized COVID-19 patients have a history of heart failure

A history of heart failure was also associated with longer lengths of stay and an increased risk of mechanical ventilation.

READ MORE >
Covid Fight
Share on Twitter Share on Facebook Share on Linkedin

Risk of death nearly doubles when hospitalized COVID-19 patients have a history of heart failure

Share on Twitter Share on Facebook Share on Linkedin
Covid Fight
A history of heart failure was also associated with longer lengths of stay and an increased risk of mechanical ventilation.
READ MORE >

Empagliflozin improves outcomes for non-diabetic HFrEF patients

Treatment with empagliflozin for six months was associated with several key improvements. This suggests that, yes, SGLT2 inhibitors can be recommended for HFrEF patients who don't have diabetes. 

READ MORE >
USPSTF updates its stance on aspirin use to prevent CVD, sees no benefit for patients 60 or older.
Share on Twitter Share on Facebook Share on Linkedin

Empagliflozin improves outcomes for non-diabetic HFrEF patients

Share on Twitter Share on Facebook Share on Linkedin
USPSTF updates its stance on aspirin use to prevent CVD, sees no benefit for patients 60 or older.
Treatment with empagliflozin for six months was associated with several key improvements. This suggests that, yes, SGLT2 inhibitors can be recommended for HFrEF patients who don't have diabetes. 
READ MORE >

Keto diet can prevent, and potentially reverse, heart failure

The increasingly popular ketogenic diet could be a valuable tool in the fight against heart failure, according to a new study published in Nature Metabolism.

READ MORE >
Share on Twitter Share on Facebook Share on Linkedin

Keto diet can prevent, and potentially reverse, heart failure

Share on Twitter Share on Facebook Share on Linkedin
The increasingly popular ketogenic diet could be a valuable tool in the fight against heart failure, according to a new study published in Nature Metabolism.
READ MORE >

Cardiologists uncover a new way to reverse heart damage—no transplant or lifelong LVAD use required

The research, published in Circulation, focused on the combination of pharmacologic therapy and the temporary use of a left ventricular assist device.

READ MORE >
Share on Twitter Share on Facebook Share on Linkedin

Cardiologists uncover a new way to reverse heart damage—no transplant or lifelong LVAD use required

Share on Twitter Share on Facebook Share on Linkedin
The research, published in Circulation, focused on the combination of pharmacologic therapy and the temporary use of a left ventricular assist device.
READ MORE >

COVID-19 patients with a history of heart failure face considerably worse outcomes

In-hospital mortality, myocardial injury and acute kidney injury were all more common when patients with a history of heart failure tested positive for COVID-19. 

READ MORE >
hospitalized
Share on Twitter Share on Facebook Share on Linkedin

COVID-19 patients with a history of heart failure face considerably worse outcomes

Share on Twitter Share on Facebook Share on Linkedin
hospitalized
In-hospital mortality, myocardial injury and acute kidney injury were all more common when patients with a history of heart failure tested positive for COVID-19. 
READ MORE >

Catheter ablation improves LVEF, boosts survival for heart failure patients with atrial fibrillation

Catheter ablation was consistently linked to more substantial LVEF improvements than pharmacological therapy.

READ MORE >
Share on Twitter Share on Facebook Share on Linkedin

Catheter ablation improves LVEF, boosts survival for heart failure patients with atrial fibrillation

Share on Twitter Share on Facebook Share on Linkedin
Catheter ablation was consistently linked to more substantial LVEF improvements than pharmacological therapy.
READ MORE >

Vericiguat ineffective for patients with worsening HFpEF

The analysis included data from nearly 800 patients with a history of chronic heart failure. 

READ MORE >
Driven by its strategic goal to advance equity in the U.S. healthcare innovation sector, the American Medical Association (AMA) recently announced an initiative that supports leading industry stakeholders in committing to equitable health innovation opportunities targeted to improving health outcomes in historically marginalized communities. #Healthdisparities 
Share on Twitter Share on Facebook Share on Linkedin

Vericiguat ineffective for patients with worsening HFpEF

Share on Twitter Share on Facebook Share on Linkedin
Driven by its strategic goal to advance equity in the U.S. healthcare innovation sector, the American Medical Association (AMA) recently announced an initiative that supports leading industry stakeholders in committing to equitable health innovation opportunities targeted to improving health outcomes in historically marginalized communities. #Healthdisparities 
The analysis included data from nearly 800 patients with a history of chronic heart failure. 
READ MORE >

Innovate Healthcare thanks our partners for supporting our newsletters.
Sponsorship has no influence on editorial content.

Interested in reaching our audiences, contact our team

*|LIST:ADDRESSLINE|*

You received this email because you signed up for newsletters from Innovate Healthcare.
Change your preferences or unsubscribe here

Contact Us  |  Unsubscribe from all  |  Privacy Policy

© Innovate Healthcare, a TriMed Media brand
Innovate Healthcare

Recent Newsletters

Week in Review: Former ACC president dies | Administration questions vascular care | Is coffee bad for the heart | FFR-CT guide
New-look pacemaker uses ultrasound to stimulate the heart | Heartflow reports significant revenue growth | CCTA & CTO PCI
New FFR-CT standardization consensus document | FDA clears first tricupid surgical valve | ECG AI to detect amyloidosis
Shockwave Medical's new IVL catheter | BATMAN to the rescue | Antiplatelet drugs after PCI | FDA announces recalls
When TAVR patients require surgery later in life | Colleagues pay tribute to a cardiology powerhouse | Much more
TAVR Highlights: Self-expanding valves continue to impress | A new technique | Why implant depth matters | SAPT vs. DAPT
Recall announced after 3 injuries | Medical societies respond to government report | New-look pacemaker requires no implant

Pagination

    • Current page 1
    • Page 2
    • Page 3
    • Page 4
    • Page 5
    • Page 6
    • Page 7
    • Page 8
    • Page 9 …
    • Next page ››
    • Last page Last »
  • Home
  • News
  • Article Archive
  • Custom Content
  • Webinars
  • Press Releases
  • Content Studio
  • Advertising
  • Submit Press Release
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Cardiovascular Business
  • HealthExec
  • Radiology Business
 
© 2026 Innovate Healthcare | All Rights Reserved. | Terms of Use | Privacy Policy
 
Design by Adaptive Theme